-An in vivo study of the tissue and cellular distribution of isotopically-labelled chlorambucil (586 mCi/mmole) in rats bearing a chlorambucil-sensitive or chlorambucil-resistant Yoshida ascites sarcoma has therefore been made in an attempt to elucidate the metabolic fate and mode of action of this drug.
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Drug uptake into the body tissue was rapid, with a high level of radioactivity being associated with the plasma and ascitic fluid during the initial 6-hour period after treatment. Previous studies in vitro had shown that chlorambucilresistant cells accumulated less drug than their sensitive counterparts: this discrepancy was also observed after in vivo drug treatment and was reflected in the two-fold difference in extent of binding of tritium to DNA, RNA and protein isolated from the 2 cell strains. These results might in part explain the observed difference in metabolism of chlorambucil by the resistant and sensitive strain of Yoshida ascites sarcoma cells.
CHLORAM13UCIL has been used extensively for the treatment of chronic lymphoblastic leukaemia (Boesen et al., 1964) , but the development of resistance to the drug has restricted its usefulness. An understanding of the factors responsible, particularly its mode of action, transport and tissue distribution might lead to a wider application of this drug in cancer chemotherapy. At present there is no detailed information concerning these factors, in either experimental animals or men.
-An in vivo study of the tissue and cellular distribution of isotopically-labelled chlorambucil (586 mCi/mmole) in rats bearing a chlorambucil-sensitive or chlorambucil-resistant Yoshida ascites sarcoma has therefore been made in an attempt to elucidate the metabolic fate and mode of action of this drug.
MATERIALS AND METHODS
Full details of tumour transplantation techniques have been described previously (Harrap and Hill, 1969) . Tritium-labelled chlorambuc'll 4-(4-di-(2-chloroethyl)amino-3,5_3H phenyl)butyric acid was synthesized by the reductive tritiation of the iodinated derivative in the Chester Beatty Research Institute (Jarman, unpublished work, 1970 (Harrap. and Hill, 1969 (Munro and Fleck, 1966) .
Aliquots of these extracts were assayed for radioactivity using a ToluenePhosphor scintillant in a Packard TriCarb Liquid Scintillation Counter Model 3375.
DNA was estimated according to Burton (1956) , RNA by the orcinol procedure (Brown, 1946) and protein by the method of Lowry, Rosebrough, Farr and Randall (1951) .
Each calculated figure represents the mean value of duplicate experimental samples from 3 animals.
RESULTS
Following subcutaneous injection of 3H-chlorambucil, drug uptake into the body tissues was rapid. After 1, hour's exposure to the drug, of the tissues studied, the higheSt 3H-concentration was found in the liver. The tissue concentrations
The following abbrev'at'ons will be tised throughout this paper: PBS-phosphate buffered saline: TEH-tetraethylammonium hydroxide.
of labelled material expressed as a fraction of the corresponding liver value (86 x 103 DPM/mg. wet weight of tissue) are shown in Table 1 . It should be noted that after this initial interval (I hour after treatment) the concentration of tritium increased in kidney, but the levels in the other tissues decreased with respect to time, the tritium being cleared most rapidly from the liver.
In whole blood the radioactive label was mainly associated with the plasma: the tritium concentration in blood and ascitic fluid was similar. A high level of radioactivity was associated with these fluids throughout the first 6-hour period following treatment (Table 11 ).
In none of these measurements were there significaiit differences in the extent of drug binding to tissues or fluids in animals bearing either the druff-sensitive zn The data presented above are concerned only with measurements of tritium concentrations in the body tissues and no attempt has been made in these experiments to identify any of the chlorambucil metabolites with which the tritium label may be associated. A detailed study of these metabolites is at present under investigation in these laboratories.
The results of the study described here indicate a relatively uniform distribution of tritium after the administration of 3 H-chlorambucil to tumour-bearing rats, in accord with the data of Milner, Klatt, Young and Stehlin (I 965), who failed to detect any significant localization of isotopes in specific tissues in studies with 2-chloroethyl derivatives. In these experiments tritium concentrated primarily in liver and kidney. This was anticipated since a function of these organs is to protect the host from any adverse effects of foreign substances. Accumulation of label in most organs was maximal within I hour except in kidney where the concentration of tritium increased during the initial 24-hour period of study.
The progressive rapid loss of label from the liver after initial uptake, was similar to data presented by Connors and Melzack (Harrap and Hill, 1970; Hill, Jarman and Harrap, 1971) . However, after the in vivo treatment described above, the initial uptake of the drug by the cells was similar (i.e. I hour after treatment). Only after this period of time was the difference between the 2 cell strains apparent. These results might be explained by reference to the different metabolism of the drug by these cells in vitro, namely that the resistant cells have a greater ability to hydrolyse and metabolize the drug (Harrap and Hill, 1970 (Hill, Jarman and Harrap, 1971) . Furthermore, it is only after, or coincident with this period that peak binding to cell macromolecules in both cell strains is noted, which would support the hypothesis that there can be slow release from this lipophylic association followed by subsequent binding to protein and nucleic acids. These data would suggest that chlorambucil may exert a cytotoxic effect by intracellular binding over a much longer period than might be assumed from its short chemical half-life and rapid rate of hydrolysis (Ross, 1962) , especially in the drug-sensitive ascites cell. These findings may also be related to the clinical observation that chemotherapy with chlorambucil only produces a maximal effect several months after its administration to the patient (Boesen and Davis, 1969) . Attempts are now being made to isolate the metabolites produced and to characterize more fully the identity of the compound which possesses these lipophylic properties (i.e. whether under these conditions it retains an active mustard group). The fact that peak cellular binding of tritium in sensitive cells occurred only 12 hours after treatment, which is much later than with Melphalan (Ball et al., 1966) , may also serve to emphasize individual differences between alkylating agents and could be related to the much delayed effects that chlorambucil, in contrast to Melphalan, has on the growth rates of the chlorambucil-sensitive Yoshida ascites cells (Harrap and Hill, 1969) : in drug-sensitive tumour-bearing animals, no effect on the growth is observed until 24 hours after treatment.
Whilst peak macromolecular binding in the sensitive cells occurred only 6 hours after maximum drug uptake, this delay was not apparent in the resistant cells, with peak binding occurring 6 hours after treatment; this effect may be associated with differing metabolism of the drug, and more details of the identity of the binding species must be obtained in order to determine the significance of these findings.
Work with 1-(2-chloroethyl)-3-cyclohexyl-l-nitrosourea (Oliverio, Vietzke, Williams and Adamson, 1970) has demonstrated that it is the cyclohexyl portion of the molecule and not the chloroethvl seLyment which is bound to protein. Since the active mustard group of chlorambucil cannot be detected in the plasma or urine 6 hours after treatment, this may mean that the binding after treatment which occurs at this period, and subsequently in the cells, may also involve another part of the chlorambucil molecule other than the 2-chloroethyl groups.
